P-263Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC). (20th June 2018) - Avallone, A; Nasti, G; Rosati, G; Carlomagno, C; Romano, C; Bilancia, D; De Stefano, A; Silvestro, L; Ottaiano, A; Cassata, A; Bianco, F; Izzo, F; et al.